Our precision oncology activities are focused on the development and implementation of methods and tools to identify actionable genomic alterations in cancer. Particular emphasis is on using an integrated approach in the evaluation of somatic (tumor) and the background germline (constitutional) genomic data to inform the role of germline alterations in cancer and their effect on the clinical management and therapeutic decisions. To date, we have demonstrated the utility of tumor-derived somatic data in the assessment of pathogenicity of germline variants in several cancer syndromes.

INT²GRATE (INTegrated INTerpretation of GeRmline And Tumor gEnomes) refers to cancer-specific programs we developed to identify germline alterations with clinical utility. The INT²GRATE Oncology Consortium is a multi-institution, international collaboration that utilizes INT²GRATE to provide comprehensive assessment of the actionability of germline variants in their specific relevance to cancer. The INT²GRATE variant Data Portal is a public-facing interface designed to make integrated variant data and comprehensive clinical evidence accessible, facilitating data sharing and cross-institutional collaboration.